Navigation Links
PTC Therapeutics Receives $2.6 Million in Government Grants
Date:6/15/2009

- Funding supports continued focus on rare disorders -

SOUTH PLAINFIELD, N.J., June 15 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC) today announced the receipt of two government grants to support clinical development programs in rare disorders. The U.S. Department of Defense Neurofibromatosis Research Program has awarded an $822,345 grant to support a new open-label Phase 2 clinical trial of PTC's product candidate PTC299 in neurofibromatosis type 2 (NF2), a rare genetic tumor. Separately, the Food and Drug Administration (FDA) Office of Orphan Products Development has awarded PTC a four-year, $1.6 million grant towards its ongoing pivotal trial of ataluren (PTC124(TM)) in nonsense mutation Duchenne and Becker muscular dystrophy (nmDMD/BMD).

(Logo: http://www.newscom.com/cgi-bin/prnh/20010919/PTCLOGO )

"We are honored to receive these grant awards from the FDA and from the Department of Defense," said Stuart W. Peltz, Ph.D., president and Chief Executive Officer of PTC Therapeutics. "Obtaining peer-reviewed grant awards are a strong endorsement of PTC's science and support our strong commitment to developing innovative medicines in areas of high unmet medical need."

Patients with NF2, a rare genetic disorder of the central nervous system, typically develop tumors that compress the auditory nerves, often leading to deafness and problems with balance. If unchecked, NF2-related tumors may eventually damage other cranial nerves and the brainstem, becoming life threatening. Current standard treatments for NF2-related tumors include surgery and radiation therapy. VEGF plays a critical role in angiogenesis, or the formation of new blood vessels, and supports tumor growth in patients with NF2. PTC299 is a novel, orally administ
'/>"/>

SOURCE PTC Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... 2014 Appistry, Inc. , a ... the power of genomics to next-generation medicine, announced today ... Challenge . , Two Appistry staff will be ... Center for Genome Resources, and Mr. Neil Miller, director ... Kansas City. Rounding out the panel are Appistry’s Dr. ...
(Date:7/28/2014)... 2014 Research and Markets has announced ... 2014-2018" report to their offering. ... a technique used to determine the size of a particle ... crucial to analyze the size of particles as it can ... is performed to determine the behavior and nature of a ...
(Date:7/25/2014)... in each person,s digestive tract. Scientists believe that some ... harmful infections, but their role in human health is ... the role of these bacteria, a team of researchers ... fluctuations in the bacterial populations of two research subjects ... July 25 issue of the journal Genome Biology ...
(Date:7/25/2014)... Pittsburgh, PA (PRWEB) July 25, 2014 ... annual Call for Topics for Conferee Networking. These two-hour ... similar interests to meet and resolve problems, discuss new ... , The deadline to submit a topic for consideration ... at pittcon.org . The Conferee Networking committee will ...
Breaking Biology Technology:Appistry Names Industry Experts from the National Center for Genome Resources and Mercy Children's, Kansas City, to Judge Pipeline Challenge Competition 2Global Particle Size Analysis Market 2014-2018 2Monitoring the rise and fall of the microbiome 2Monitoring the rise and fall of the microbiome 3Pittcon 2015 Announces Call for Topics for Conferee Networking Sessions 2
... Authorities to Launch Final ... Clinical Trial for Asacard(R), NEW ... appointment of Dr. Geert Cauwenbergh as Chief Executive,Officer. Dr. Cauwenbergh ... assisting RHEI Pharmaceuticals since August 1, 2008,in providing the necessary ...
... (IPM) today announced it was named to Inc. ... companies nationwide for a second consecutive year. The ... broad range of industries, helping companies operate more ... one of the Chicago area’s top 100 businesses, ...
... Mymetics,Corporation (OTCBB:MYMX) announced today that its ... & Poor,s Market Access Program, an,information distribution ... have their company information disseminated to users ... information to be made,available through this program ...
Cached Biology Technology:RHEI Pharmaceuticals Appoints Dr. Geert Cauwenbergh as Chief Executive Officer 2RHEI Pharmaceuticals Appoints Dr. Geert Cauwenbergh as Chief Executive Officer 3RHEI Pharmaceuticals Appoints Dr. Geert Cauwenbergh as Chief Executive Officer 4 Integrated Project Management Named to "Inc. 5000" for Second Year : One of the Top 100 Fastest-Growing Companies in Chicago Area 2Mymetics Corporation Information to be Available Through Standard & Poor's Market Access Program 2
(Date:7/27/2014)... date, researchers from the U.K. provide national, regional, and ... (HCV). Findings published in Hepatology, a journal of the ... that genotype 1 is the most prevalent worldwide, with ... in East Asia. Genotype 3, at just over 54 ... genotypes 2, 4, 6, and 5. , Despite ...
(Date:7/27/2014)... Barts Cancer Institute have found that targeting a molecule ... effective, according to research published in Nature ... of Queen Mary University of London, have found that ... body to repair itself after chemotherapy or radiotherapy, which ... removed FAK from blood vessels that grew in melanoma ...
(Date:7/25/2014)... 100,000s of people lived on the land now called ... control the availability of plants they used for food, ... fire to maintain desired habitat and natural resources. , ... Pacific Southwest Station, will lead a field trip ... the Ecological Society of America,s 99th Annual Meeting, in ...
Breaking Biology News(10 mins):Hepatitis C virus genotype 1 is most prevalent worldwide 2New drug target can break down cancer's barrier against treatment 2Fire ecology manipulation by California native cultures 2Fire ecology manipulation by California native cultures 3
... Calif., Jan. 10, 2011 Based on its ... Frost & Sullivan recognizes Cardiocom with the 2011 ... Technology. Cardiocom provides integrated clinical telehealth services that ... (Logo:   http://photos.prnewswire.com/prnh/20081117/FSLOGO ) ...
... Dry Copper Kills Bacteria on Contact ... their populations, according to a paper in the February ... Microbiology . They do so literally in minutes, by ... says the study,s corresponding author, Gregor Grass of the ...
... China, Feb. 1, 2011/PRNewswire-Asia-FirstCall/ -- Weikang Bio-Technology Group ... ) ("Weikang" or the "Company"), a leading developer, ... Western prescription and OTC pharmaceuticals and other health ... China, today announced the completion of its private ...
Cached Biology News:Frost & Sullivan Recognizes Cardiocom as a Technology Enabler for Superior Cost-Effective Remote Chronic Care Management 2Frost & Sullivan Recognizes Cardiocom as a Technology Enabler for Superior Cost-Effective Remote Chronic Care Management 3Frost & Sullivan Recognizes Cardiocom as a Technology Enabler for Superior Cost-Effective Remote Chronic Care Management 4Tips from the journals of the American Society for Microbiology 2Tips from the journals of the American Society for Microbiology 3Tips from the journals of the American Society for Microbiology 4Tips from the journals of the American Society for Microbiology 5Tips from the journals of the American Society for Microbiology 6Tips from the journals of the American Society for Microbiology 7Weikang Bio-Technology Announces Completion of $5.0 Million Private Placement 2Weikang Bio-Technology Announces Completion of $5.0 Million Private Placement 3
Chicken Aortic Smooth Muscle Cells (CAOSMC) (>500,000 cells)...
... Hot Start Taq Monoclonal ... before the onset of ... amplification and primer-dimer formation. ... raised, the antibody is ...
... Workstation brings together UV irradiation and antimicrobial ... against PCR contamination! Quickly inactivate DNA ... a clean environment with antimicrobial coated stainless ... within minutes with built-in 30-minute timer ...
... The flexible and easy ... used to control all members ... family. It features a clear ... visual assay setup, user-friendly and ...
Biology Products: